Full Press Release Details
Eidos Therapeutics Initiates First Clinical Study For AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis As Chief Business Officer.
BBIO
Eidos Therapeutics Initiates First Clinical Study For AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis As Chief Business Officer
Key Takeaway: Eidos Therapeutics Initiates First Clinical Study For AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis As Chief Business Officer